美诺华 20250625 摘要 美诺华正推进创新益生菌药物 389 产品，该产品旨在通过调节肠道菌群， 实现降糖、减重等效果，计划以保健品形式在欧洲注册，并通过跨境电 商等方式进入国内市场，预计最快 2026 年第一季度实现商业化销售。 389 产品目前定位为非药产品，目标市场包括保健品、食品添加剂和新 食品成分。公司计划先通过保健品或新食品成分的审批，再进行小规模 临床试验，以反推产品的有效性，未来或将开发双靶或三靶药物。 389 产品在欧洲和美国市场的注册及上市时间进度方面，安全性实验预 计需要六个月时间，最早可能在 2026 年第一季度上市。在安全性实验 结束后，将以数据模型及佐证材料申报备案。 美诺华对 389 产品的市场空间估算主要基于两类人群：一是使用规划类 生物治疗药物后进入戒断期的人群，二是希望减肥但不愿意接受打针和 吃药的人群，预计前者市场规模可达 50~60 亿美元/年。 美诺华已对 J389 产品进行了深度专利保护，并已递交了专利申请，预计 两周内会获得专利号。公司与美国和欧洲合作方签订了许可协议，后续 在欧洲注册、安全性实验等费用均由合作方承担，美诺华享有约 8%的 收入分成。 Q&A ...

生物制造领域有哪些 "潜力股" 团队、技术和产品值 得关注？ 为发掘合成生物学和生物制造科研团队创新成果、 促进生物制造领域优秀科研工作者成果交流和产业方对接， 第四届合成生物与绿色生物制造大会 (简称： SynBioCon 2025 ) 同期将举办特色专场——" 生物制造青年论坛 "，于8月20日在浙江宁波举办。 助力行业 15分钟了解一个方向 ，重点阐述研究领域存在的科学问题、解决思路、成果、放大可行性以及未来发展方向。 欢迎高校、科研院所申报分享！ 扫码报名，请选择参会形式 报名请选择：青年论坛、科技成果展示 SynBioCon 2 025 8月20-22日，浙江·宁波 SynBioCon 大会 | 生物制造青年论坛 特色专场 生物制造青年论坛 8月20日，浙江·宁波 01 论坛信息 时 间： 8月20日（周三） 席 位 ： 仅 30 席！ 报告时间： 第一场：13:30-17:30； 第二场：19:00-20:30 报名须知 ：扫描以上二维码，会务组将第一时间与您确认，并对接报告信息表等； 02 科技成果展示与对接专场 （同期活动） SynBioCon 2025 将设置 「科技成果展示与对接」专场 （ ...

Core Viewpoint - The article discusses the advancements in synthetic biology tools for customizing yeast cell factories, highlighting their potential in producing high-value compounds efficiently [3]. Group 1: Innovative Tools for Yeast Cell Factories - The paper titled "Innovative tools for customized yeast cell factory" outlines significant progress in synthetic biology tools, including genome editing, computational tools, adaptive laboratory evolution, and standardization of biological DNA components [3]. - These tools aim to provide practical guidelines for the effective development of customized yeast cell factories [3]. Group 2: Genome Editing Tools - Genome editing has evolved from single-gene editing to simultaneous multi-gene editing, with CRISPR-Cas systems enabling precise modifications in yeast genomes, including knockouts, insertions, and replacements [6]. - New variants of CRISPR-Cas, such as base editing and prime editing, allow for single nucleotide changes to alter gene functions [6]. Group 3: Computational Tools - Computational tools, including metabolic modeling and the integration of omics technologies, guide engineering strategies and expected flux adjustments [7]. - Genome-scale metabolic models (GEMs) have been widely applied in yeast metabolic engineering, with large-scale kinetic models playing a crucial role in designing and understanding metabolic reactions [7]. Group 4: Adaptive Laboratory Evolution - Adaptive laboratory evolution (ALE) is a powerful strategy for enhancing yeast strain performance by applying selective pressure over generations, leading to the emergence of more adaptive strains [8]. - Combining ALE with whole-genome sequencing helps identify beneficial mutations and provides insights into the genetic basis of adaptability [8]. Group 5: Standardization of Biological DNA Components - The increasing complexity of yeast cell factory designs necessitates precise control and regulation of biological components, gene circuits, or biological systems [9]. - Synthetic biology offers standardized biological components, allowing researchers to assemble these components into complex systems with predictable behaviors [9].

Core Viewpoint - The research team at Sichuan University is leveraging synthetic biology to develop a cost-effective production method for spermidine, a natural polyamine with significant applications in anti-aging and cardiovascular disease prevention, which is projected to become a billion-dollar bioactive molecule [2][3]. Group 1: Technology and Innovation - The production of spermidine has been hampered by high costs and technical bottlenecks, with traditional extraction methods yielding only 1% purity and chemical synthesis being prohibitively expensive [3][4]. - The team has utilized machine learning algorithms to simulate yeast metabolic networks, significantly enhancing spermidine synthesis efficiency [4]. - A breakthrough was achieved by discovering an extracellular secretion mechanism that allows spermidine to be actively expelled from cells, improving purity and reducing energy consumption during extraction [5]. Group 2: Market and Application - Spermidine is positioned to drive multiple billion-dollar industries, with products in the food sector entering trial production and clinical trials for cardiovascular disease prevention underway in the pharmaceutical sector [7]. - A report from McKinsey Global Institute indicates that 60% of industrial products could be manufactured using biotechnology, with synthetic biology expected to generate $2-4 trillion in direct economic benefits annually between 2030 and 2040 [7]. Group 3: Policy and Industry Collaboration - Chengdu has emerged as a hub for synthetic biology, with various local governments implementing supportive policies, facilitating the transition from technology to market applications [8]. - The collaboration between universities and enterprises is crucial for addressing real market needs, ensuring that research is aligned with practical applications [9].

SynBioCon 大会 | 生物制造青年论坛 特色专场 生物制造青年论坛 8月20日，浙江·宁波 02 科技成果展示与对接专场 （同期活动） SynBioCon 2025 将设置 「科技成果展示与对接」专场 （现场展示科技成果推介墙）， 公开征集100个从0—1—100的合成生物和生物制造领域创新成果 和项目 ，于现场展示、对接。 生物制造领域有哪些 "潜力股" 团队、技术和产品值 得关注？ 为发掘合成生物学和生物制造科研团队创新成果、 促进生物制造领域优秀科研工作者成果交流和产业方对接， 第四届合成生物与绿色生物制造大会 (简称： SynBioCon 2025 ) 同期将举办特色专场——" 生物制造青年论坛 "，于8月20日在浙江宁波举办。 助力行业 15分钟了解一个方向 ，重点阐述研究领域存在的科学问题、解决思路、成果、放大可行性以及未来发展方向。 欢迎高校、科研院所申报分享！ 扫码报名，请选择参会形式 报名请选择：青年论坛、科技成果展示 SynBioCon 2 025 8月20-22日，浙江·宁波 01 论坛信息 时 间： 8月20日（周三） 席 位 ： 仅 30 席！ 报告时间： 第一场：13:30 ...

Core Viewpoint - The article discusses the innovative approach of Yike Biotech in reducing the cost of PHA (polyhydroxyalkanoates) production to compete with petroleum-based materials, emphasizing the use of non-food plant oils as raw materials [3][4][9]. Group 1: Industry Background - The biodegradable materials market, including PLA and PBAT, has faced challenges such as overcapacity and performance limitations, leading to a decline in production rates [6][7]. - PHA is highlighted for its advantages, including marine biodegradability, heat resistance up to 100°C, and excellent barrier properties, with the global market expected to reach $367 million by 2030 [6][8]. Group 2: Company Overview - Yike Biotech was founded in June 2025 by Dr. Wilson Ling, who aims to revolutionize PHA production using non-food oils, specifically Pongamia oil, to significantly lower costs [9][10]. - The company has completed laboratory and pilot-scale validations of its production process and is the first globally to hold a PCT patent for PHA production [37]. Group 3: Cost Reduction Strategy - The raw material cost constitutes over 50% of PHA production costs, making it essential to lower these costs. Traditional sugar-based routes have a conversion rate of only 30%, leading to high costs [27][28]. - By using Pongamia oil, which has a conversion rate of over 80%, Yike Biotech can reduce PHA production costs by 30-50% compared to sugar-based methods [36]. Group 4: Technical and Market Development - Yike Biotech plans to focus on medical products for the Australian market, where demand is high, and the approval process is faster compared to other regions [38]. - The company aims to establish a production line in China that can replace 15,000 to 20,000 tons of petroleum-based plastics annually, with plans for further expansion [39].

全球政策进展 | 上海市 2025 年度关键技术研发计划 "合成生物学 "项目立项清单 | 序号 | 1 | | --- | --- | | 项目编号 | 25HC2810100 | | | 基于喷墨打印微阵列芯片的高通量高精度 | | 项目名称 | 低成本长片段核酸合成 | | 项目承担单位 | 上海迪赢生物科技有限公司 | | 项目负责人 | 张满仓 | | 项目实施周期 | 2025.08.01-2028.07.31 | | 序号 | 2 | | 项目编号 | 25HC2810200 | | 项目名称 | 高通量长片段 DNA 酶促合成系统研发 | | 项目承担单位 | 上海人工智能研究院有限公司 | | 项目负责人 | 夏 凯 | | 项目实施周期 | 2025.08.01-2028.07.31 | | 序号 | 3 | 项目编号 25HC2810300 项目名称 重要天然产物生物合成功能元件挖掘及共 享元件库的构建 项目承担单位 上海中医药大学 项目负责人 陈万生 项目实施周期 2025.08.01-2028.07.31 序号 4 项目编号 25HC2810400 项目名称 生物合成新元件的挖掘表征 ...

Core Viewpoint - Vitamin A is essential for human health, supporting vision, immune regulation, and serving as a key ingredient in anti-aging cosmetics. Traditional chemical synthesis methods for Vitamin A are complex and costly, leading to a shift towards green biomanufacturing using synthetic biology techniques [1][6]. Group 1: Research Findings - A recent study by Zhejiang University has engineered yeast to enhance Vitamin A production by modifying transporter systems, energy metabolism, and precursor supply networks, achieving unprecedented yields [1][6]. - The hydrophobic nature of Vitamin A leads to accumulation within cells, increasing metabolic burden and affecting synthesis efficiency. Approximately 17-20% of retinol remains unextracted during high-density fermentation, limiting production [2]. - The research team introduced transporter engineering strategies, identifying key transport proteins that facilitate the synthesis and secretion of retinol, retinal, and retinoic acid [2]. Group 2: Engineering Strategies - The team optimized the yeast's energy metabolism by overexpressing FZO1 and MGM1 to enhance mitochondrial fusion and introducing Vgb to improve oxygen uptake, thereby increasing ATP levels and energy supply [3]. - A multi-faceted engineering approach, combining transporter engineering, energy metabolism enhancement, and precursor supply optimization, led to significant breakthroughs in yeast strains for Vitamin A production [3][4]. Group 3: Production Results - Post-engineering, the yeast strain achieved a retinal yield of 638.12 mg/L with an extracellular ratio of 98.7%, and a retinoic acid yield of 106.75 mg/L, both representing the highest reported shake flask yields to date [4]. - The engineered yeast strain produced 727.30 mg/L of retinol with a carbon conversion rate of 7.62% using 20 g/L glucose, surpassing previous best strains [4]. Group 4: Implications for Industry - This research provides new insights for the efficient biomanufacturing of Vitamin A and serves as a reference for the green production of other high-value lipophilic products [6]. - As synthetic biology technologies advance, microbial cell factories are expected to play a crucial role in future biomanufacturing, contributing to human health and sustainable development [6].

上海市科学技术委员会6月23日发布关于2025年度关键技术研发计划"合成生物学"项目立项的通知。根 据《上海市科学技术委员会关于发布2025年度关键技术研发计划"合成生物学"项目申报指南的通知》 （沪科指南〔2025〕8号）要求，经申报推荐、形式审查、专家评审、立项公示等程序，现对《基于喷 墨打印微阵列芯片的高通量高精度低成本长片段核酸合成》等18个项目予以立项，市科委资助4200万 元，其中2025年拨款3210万元。（上海市科学技术委员会网站） ...

"此次大会以'发展合成生物，培育未来产业'为主题，恰逢其时，意义深远。"中国生物发酵产业协会理 事长于学军说，"我们应聚焦关键，精准发力。一是强化科技创新引领，持续加大投入，鼓励高校、科 研机构与企业携手，开展联合攻关，突破关键技术瓶颈，释放创新活力，提升关键领域的核心竞争力， 让科技创新成为产业发展的强大引擎；二是促进产业协同发展，加强产业链上下游企业间的合作，形成 产业集群效应，推动合成生物学技术在医药、食品、农业、化工、能源等多领域的广泛应用，实现跨产 业的深度融合与协同发展，构建起互利共赢的产业生态；三是加强人才培养与引进，合成生物学作为一 门交叉学科，对复合型人才的需求迫切，应加强高校相关专业建设，完善人才培养体系，同时积极引进 海外高层次人才，为产业发展注入源头活水，提供坚实的人才保障；四是完善政策生态体系，政府部门 需精准施策，制定针对性政策，在税收优惠、财政补贴、项目支持等方面给予产业更多扶持，为合成生 物学产业的茁壮成长创造良好的政策环境，助力产业腾飞。" 本报讯 （记者 闫 利）日前，2025合成生物学技术创新发展大会在江苏宜兴举行。大会以"发展合成生 物 培育未来产业"为主题，8位两院院 ...